VR Adviser’s Damora Therapeutics DMRA Stock Holding History

VR Adviser’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$93.7M	Hold	3,603,595	–	–	2.84%	7
2026 Q1	$93.3M	Buy	+3,603,595	New	+$92.6M	3.48%	7

Other funds holding DMRA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Jupiter Topco New York $245B AUM

RCP

Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

VR Adviser's DMRA Position: Q2 2026 in Review

VR Adviser held its Damora Therapeutics (DMRA) position steady in Q2 2026 at 3,603,595 shares worth $93.7M. The position accounts for 2.84% of the portfolio, ranked #7.

VR Adviser first reported a position in DMRA in Q1 2026 and has held it in 2 quarters since. 104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

VR Adviser held 3,603,595 shares of Damora Therapeutics worth $93.7M as of Q2 2026.
VR Adviser left its Damora Therapeutics share count unchanged in Q2 2026.
Damora Therapeutics made up 2.84% of VR Adviser's portfolio in Q2 2026, its #7 holding.
VR Adviser first reported a position in Damora Therapeutics in Q1 2026 and has held it in 2 quarters since.
104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on VR Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.